Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Clin Pathol ; 144(3): 423-6, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26276772

ABSTRACT

OBJECTIVES: Annually, millions of pairs of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) tests are ordered. These enzymes are highly correlated, and ALT is far more specific diagnostically than AST. To reduce AST testing, we suggest measuring AST only when ALT exceeds a predetermined limit. METHODS: We derived the proportions of elevated ASTs that would not be measured based on 15 months of paired inpatient and outpatient ALT and AST data. RESULTS: For inpatients, a 35 U/L ALT limit for initiating AST testing would reduce AST testing by 51%, missing only 3% and 7.5% of ASTs exceeding 50 U/L and 35 U/L, respectively. In outpatients, AST testing can be reduced by more than 65%, with fewer missed elevated ASTs (0.5% and 2% of the ASTs exceeding 50 U/L and 35 U/L, respectively). CONCLUSIONS: Conservatively, $100 million could be saved annually in the US health care budget by selectively limiting AST testing in just the US outpatient environment.


Subject(s)
Alanine Transaminase/analysis , Aspartate Aminotransferases/analysis , Delivery of Health Care/economics , Liver Diseases/enzymology , Alanine Transaminase/economics , Aspartate Aminotransferases/economics , Humans , Liver Diseases/diagnosis , Liver Diseases/economics , Patient Selection , United States
2.
J Viral Hepat ; 17(8): 537-45, 2010 Aug.
Article in English | MEDLINE | ID: mdl-19804501

ABSTRACT

Combinations of noninvasive markers may improve discrimination of chronic liver disease severity. The aims of this study were to compare four validated serum and ultrasound-based markers of hepatic disease severity head-to-head with liver biopsy and to assess optimal combinations with consideration of cost. A total of 67 patients with biopsy-proven chronic hepatitis C underwent all four techniques on the same visit [aspartate aminotransferase (AST) to platelet ratio index (APRI); Enhanced Liver Fibrosis (ELF) panel; transient elastography (TE) and ultrasound microbubble hepatic transit times (HTT)]. Markers were combined according to increasing financial cost and ordinal regression used to determine contributions. APRI, ELF, TE and HTT predicted cirrhosis with diagnostic accuracy of 86%, 91%, 90% and 83% respectively. ELF and TE were the most reliable tests with an intra-class correlation of 0.94 each. Either ELF or TE significantly enhanced the prediction of fibrosis stage when combined with APRI, but when combined together, did not improve the model further. Addition of third or fourth markers did not significantly improve prediction of fibrosis. Combination of APRI with either ELF or TE effectively predicts fibrosis stage, but combinations of three or more tests lead to redundancy of information and increased cost.


Subject(s)
Aspartate Aminotransferases/blood , Contrast Media/pharmacology , Elasticity Imaging Techniques/methods , Hepatitis C, Chronic/pathology , Liver Cirrhosis/pathology , Adolescent , Adult , Aged , Aspartate Aminotransferases/economics , Elasticity Imaging Techniques/economics , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/diagnostic imaging , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/diagnostic imaging , Middle Aged , Platelet Count/economics , Platelet Count/methods , ROC Curve , Regression Analysis , Reproducibility of Results , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...